title: Neuronal LR11 expression does not differentiate between clinically-defined Alzheimer's disease and control brains.
abstract: Alzheimer's disease (AD) is the leading cause of dementia in the elderly. Because the pathological changes underlying this disease can begin decades prior to the onset of cognitive impairment, identifying the earliest events in the AD pathological cascade has critical implications for both the diagnosis and treatment of this disease. We previously reported that compared to autopsy confirmed healthy control brain, expression of LR11 (or SorLA) is markedly reduced in AD brain as well as in a subset of people with mild cognitive impairment (MCI), a prodromal clinical stage of AD. Recent studies of the LR11 gene SORL1 have suggested that the association between SORL1 single nucleotide polymorphisms (SNPs) and AD risk may not be universal. Therefore, we sought to confirm our earlier findings in a population chosen solely based on clinical criteria, as in most genetic studies. Quantitative immunohistochemistry was used to measure LR11 expression in 43 cases from the Religious Orders Study that were chosen based on a final pre-mortem clinical diagnosis of MCI, mild/moderate AD or no cognitive impairment (NCI). LR11 expression was highly variable in all three diagnostic groups, with no significant group differences. Low LR11 cases were identified using the lowest tertile of LR11 expression observed across all cases as a threshold. Contrary to previous reports, low LR11 expression was found in only 29% of AD cases. A similar proportion of both the MCI and NCI cases also displayed low LR11 expression. AD-associated lesions were present in the majority of cases regardless of diagnostic group, although we found no association between LR11 levels and pathological variables. These findings suggest that the relationship between LR11 expression and the development of AD may be more complicated than originally believed.
authors.affiliation: Center for Neurodegenerative Disease, Emory University, Atlanta, Georgia, United States of America.
authors.forename: Kristen L
authors.initials: KL
authors.lastname: Sager
authors.forename: Joanne
authors.initials: J
authors.lastname: Wuu
authors.forename: Jeremy H
authors.initials: JH
authors.lastname: Herskowitz
authors.forename: Elliott J
authors.initials: EJ
authors.lastname: Mufson
authors.forename: Allan I
authors.initials: AI
authors.lastname: Levey
authors.forename: James J
authors.initials: JJ
authors.lastname: Lah
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000378:metabolism* / Q000473:pathology*; D001921:Brain / Q000166:cytology / Q000378:metabolism / Q000473:pathology*; D016022:Case-Control Studies; D060825:Cognitive Dysfunction / Q000150:complications; D005625:Frontal Lobe / Q000378:metabolism / Q000473:pathology; D005786:Gene Expression Regulation; D006801:Humans; D026502:LDL-Receptor Related Proteins / Q000378:metabolism*; D008297:Male; D026901:Membrane Transport Proteins / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism* / Q000473:pathology
chemical_list: D026502:LDL-Receptor Related Proteins; D026901:Membrane Transport Proteins; C102582:SORL1 protein, human